Indomethacin and pancreatic enzymes synergistically damage intestine of rats.
The use of high-dose pancreatic enzymes by patients with cystic fibrosis was associated with the development of fibrosing colonopathy. Preliminary studies indicated that the infusion of high-dose pancreatic enzymes alone did not cause intestinal damage. We hypothesized that cystic fibrosis patients that developed fibrosing colonopathy had increased intestinal permeability. Our goal was to develop a rat model for pancreatic enzyme-induced fibrosing colonopathy by increasing intestinal permeability with the use of indomethacin. Pancreatic enzymes, 150,000 units/kg/day, and indomethacin, 3 mg/kg/day, alone and in combination were administered via duodenal catheter to rats for 10 days. Indomethacin and pancreatic enzymes caused intestinal damage, resulting in significant increases in the total number of ulcers (P < 0.007), the number of severe ulcers (P < 0.003), and ulcers in the cecum and colon (P < 0.0007). We conclude that the combination of indomethacin and pancreatic enzymes acts synergistically to cause damage to the intestine.
Kimura
R E
RE
Department of Pediatrics, Rush Medical College, Rush Children's Hospital, Chicago, Illinois 60612, USA.
Arango
V
V
Lloyd-Still
J
J
D000818:Animals; D002404:Catheterization; D003106:Colon / Q000187:drug effects / Q000473:pathology; D003108:Colonic Diseases / Q000139:chemically induced / Q000473:pathology; D004357:Drug Synergism; D010450:Endopeptidases / Q000008:administration & dosage / Q000009:adverse effects; D007213:Indomethacin / Q000008:administration & dosage / Q000009:adverse effects*; D007422:Intestines / Q000187:drug effects* / Q000473:pathology; D008049:Lipase / Q000008:administration & dosage / Q000009:adverse effects; D008297:Male; D010179:Pancreas / Q000201:enzymology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D014456:Ulcer / Q000139:chemically induced / Q000473:pathology
D008049:Lipase; D010450:Endopeptidases; D007213:Indomethacin